DENTSPLY SIRONA, Inc. XRAY

The global dental implants and prosthetics market is projected to grow from USD 12.79 billion in 2026 to USD 17.67 billion by 2031, at a 6.7% CAGR. Growth is driven by rising tooth loss, an aging population, demand for cosmetic dentistry, and advances in CAD/CAM, 3D printing and minimally invasive procedures. Dental implants and dental hospitals & clinics led the market in 2025, while Europe held the largest regional share. High treatment costs, limited reimbursement and shortages of skilled den

The global dental equipment market is projected to grow from USD 8.31 billion in 2026 to USD 11.48 billion by 2031, registering a 5.5% CAGR. Growth is driven by rising oral health disorders, demand for cosmetic and preventive dentistry, dental tourism, and adoption of digital imaging, CAD/CAM, intraoral scanners, laser dentistry, and 3D printing. Therapeutic dental equipment will hold the largest market share, while hospitals and clinics remain the leading end users. The US is expected to record

The global dental consumables market is projected to grow from USD 37.0 billion in 2026 to USD 54.0 billion by 2031, registering a 7.9% CAGR. Growth is driven by rising dental disease prevalence, aging populations, cosmetic dentistry demand, improved access to oral care, and adoption of digital dentistry and CAD/CAM technologies. Dental restoration leads by product type, while dental hospitals and clinics hold the largest end-user share. Asia Pacific is expected to record the highest CAGR, suppo

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how dental equipment & technology stocks fared in Q2, starting with Dentsply Sirona (NASDAQ:XRAY).

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

DENTSPLY SIRONA (XRAY) shares are in focus after the company reported second quarter 2026 results that returned the business to profitability while net sales declined 4.1% year over year. The latest results and upcoming appearance at the Baird 2026 Global Healthcare Conference come after a mixed share price pattern for DENTSPLY SIRONA, with a 7 day share price return of 3.53% but a 30 day share price return that declined 19.90%. Recent momentum has been choppy, as a 90 day share price return...

DENTSPLY SIRONA stock has had a difficult run over the past few years, yet on broad valuation checks it now screens as one of the cheaper options in its peer group. The share price history and the current multiples are sending very different signals about what the market expects from the business. Over the past 5 years, DENTSPLY SIRONA shareholders have seen the stock fall about 79.6%, which points to a long period of weak sentiment that still weighs on expectations today. The valuation...

Dentsply Sirona recently reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and also confirmed it will present at the Baird 2026 Global Healthcare Conference on September 15, 2026. The combination of improved profitability and cash flow, despite weaker revenue and a history of pressure on returns, led management to reiterate full-year 2026 guidance, highlighting a sharper focus on...

CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://inves

On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year earlier to $37 million in net income, with diluted earnings per share of $0.18 […]

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.